Individual Differences in Response to Antidepressants

Abstract

IMPORTANCE Antidepressants are commonly used worldwide to treat major depressive disorder. Symptomatic response to antidepressants can vary depending on differences between individuals; however, this variability may reflect nonspecific or random factors.OBJECTIVES To investigate the assumption of systematic variability in symptomatic response to antidepressants and to assess whether this variability is associated with severity of major depressive disorder, antidepressant class, or year of study publication.DATA SOURCES Data used were from a recent network meta-analysis of acute treatment with licensed antidepressants in adults with major depressive disorder. The following databases were searched from inception to January 8, 2016: the Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS database, MEDLINE, MEDLINE In-Process, and PsycINFO. Additional sources were international trial registries, drug approval agency websites, and key scientific journals.STUDY SELECTION Analysis was restricted to double-blind, randomized placebo-controlled trials with available data at the study's end point. DATA EXTRACTION AND SYNTHESISBaseline and end point means, SDs, number of participants in each group, antidepressant class, and publication year were extracted. The data were analyzed between August 14 and November 18, 2019. MAIN OUTCOMES AND MEASURESWith the use of validated methods, coefficients of variation were derived for antidepressants and placebo, and their ratios were calculated to compare outcome variability between antidepressant and placebo. Ratios were entered into a random-effects model, with the expectation that response to antidepressants would be more variable than response to placebo. Analysis was repeated after stratifying by baseline severity of depression, antidepressant class (selective serotonin reuptake inhibitors: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and vilazodone; serotonin and norepinephrine reuptake inhibitors: desvenlafaxine and venlafaxine; norepinephrinedopamine reuptake inhibitor: bupropion; noradrenergic agents: amitriptyline and reboxetine; and other antidepressants: agomelatine, mirtazapine, and trazodone), and publication year. RESULTSIn the 87 eligible randomized placebo-controlled trials (17 540 unique participants), there was significantly more variability in response to antidepressants than to placebo (coefficients of variation ratio, 1.14; 95% CI, 1.11-1.17; P < .001). Baseline severity of depression did not moderate variability in response to antidepressants. Variability in response to selective serotonin reuptake inhibitors was lower than variability in response to noradrenergic agents (coefficients of variation ratio, 0.88; 95% CI, 0.80-0.97; P = .01), as was the variability in response to other antidepressants compared with noradrenergic agents (coefficients of variation ratio, 0.87; 95% CI, 0.79-0.97; P = .001). Variability also tended to be lower in studies that were published more recently, with coefficients of variation chang...

On the treatment effect heterogeneity of antidepressants in major depression. A Bayesian meta-analysis

“…It is important to note that a VR (or CVR) sufficiently smaller than 1 is in fact evidence of relevant treatment effect heterogeneity (see supplementary figure 8 and 9). Therefore, considering the lnCVR as the main outcome would lead to the opposite conclusion of substantial treatment effect heterogeneity [36].…”

Reappraising Treatment Effect Heterogeneity in Schizophrenia: A Meta-analysis

“…Several analyses of variability based on study-level data, however, found no evidence of greater variability in the active treatment arm, and thus concluded that treatment effects are likely to be relatively constant, which suggests the scope for personalisation of treatment is limited (7)(8)(9)(10)(11)(12)(13). These findings were surprising given the widespread clinical belief that patients differ substantially in their response to medication.…”

“…Meta-analysis of variability has recently become an area of intense interest in psychiatric research. The technique has been applied to understand variability of brain structure (1), and subsequently brain function (2)(3)(4)(5), immune function (6), and more recently to investigate variability in randomised controlled trials (RCTs) of therapeutic interventions thereby potentially providing an estimate of treatment effect heterogeneity (7)(8)(9)(10)(11)(12)(13).…”

Evidence for a specific regional association between lateral orbitofrontal cortex morphometry and increased appetite in major depression

“…Response rates to standard first-line treatment such as antidepressant medication in MDD patients are modest ranging from 30-50% only [3,4]. Failure to identify the widely suspected distinct clinical and neurobiological subtypes underlying depression heterogeneity and subsequent inability to account for differing subtypes via appropriate treatment stratification is thought to represent a major cause of modest treatment success [5][6][7][8][9]. Recent psychiatric research aims to overcome this obstacle by studying depression heterogeneity and has consistently highlighted the relevance of atypical features of depression.…”